Reuters logo
BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics
September 13, 2017 / 6:32 AM / 8 days ago

BRIEF-Onxeo grants exclusive worldwide license for Validive to Monopar Therapeutics

Sept 13 (Reuters) - ONXEO SA:

* ONXEO GRANTS EXCLUSIVE WORLDWIDE LICENSE OF VALIDIVE DEVELOPED FOR THE TREATMENT OF ORAL SEVERE MUCOSITIS TO MONOPAR THERAPEUTICS

* ‍AGREEMENT INCLUDES SUBSTANTIAL MILESTONE PAYMENTS UP TO $108M AS WELL AS ESCALATING ROYALTIES ON FUTURE SALES​

* ‍MONOPAR THERAPEUTICS WILL DRIVE AND FUND ALL REMAINING DEVELOPMENT, REGULATORY AND COMMERCIALIZATION ACTIVITIES​

* ‍ONXEO IS ENTITLED TO AN IMMEDIATE $1.0M LICENSE FEE AND TO FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES​

* FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M SUBJECT TO ACHIEVEMENT OF AGREED UPON MILESTONES

* ‍ESCALATING ROYALTIES ON SALES UP TO A 2-DIGIT PERCENTAGE ARE ALSO PART OF AGREEMENT.​

* FUTURE MILESTONE PAYMENTS THAT COULD REACH UP TO $108M INCLUDING $15.5M RELATED TO REGULATORY MILESTONES, FROM PHASE III TO REGISTRATION Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below